New Delhi, Nov 23 (PTI) Aurobindo Pharma on Saturday said its US-based subsidiary has inked a licensing agreement with a global pharma major for development of respiratory products.

Aurobindo Pharma USA Inc has entered into a collaboration and licence agreement with a global pharma major for development and commercialisation of products, the Hyderabad-based drug firm said in a regulatory filing.

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for November 23, 2024 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

The partnership is for an initial estimated development duration of three-five years, it added.

As per the pact, both parties will co-exclusively commercialise the products.

Also Read | Shillong Teer Results Today, November 23 2024: Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

The products, once commercialised, will be manufactured at Partner's facility and will be marketed by both parties, Aurobindo Pharma said.

Besides a cost-sharing arrangement has been agreed by both the parties with each of them contributing 50 per cent of the cost incurred with an overall cap of USD 90 million for Aurobindo over the development period, it said.

As per the pact, the unnamed global pharma company will have the global manufacturing rights for the co-developed and commercialised products, it said.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)